Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v10-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-08-07 | 2024-06-03 |
| Drug Identification Number | 02236564 | 02236564 |
| Brand name | LOVENOX WITH PRESERVATIVE 300MG/3ML | LOVENOX WITH PRESERVATIVE 300MG/3ML |
| Common or Proper name | Lovenox 300 mg/3 mL vials | Lovenox 300 mg/3 mL vials |
| Company Name | SANOFI-AVENTIS CANADA INC | SANOFI-AVENTIS CANADA INC |
| Ingredients | ENOXAPARIN SODIUM | ENOXAPARIN SODIUM |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 1 vial | 1 vial |
| ATC code | B01AB | B01AB |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2024-06-03 | 2024-06-03 |
| Estimated end date | 2024-08-09 | 2024-07-17 |
| Actual end date | 2024-08-07 | |
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Supply delay: The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. HCPs are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. . Supply is available to market. Allocations are for protective measures. | SUPPLY DELAY: The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. HCPs are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. . Supply is available to market. Allocations are for protective measures. |
| Health Canada comments |